公开(公告)号：US20210369842A1

公开(公告)日：2021-12-02

申请号：US17289602

申请日：2019-11-06

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  A61K47/22 ,  A61K47/26 ,  A61K9/00

Abstract: The present invention relates to pharmaceutical formulations of binding agents and their use in medicine. In particular, the invention relates to pharmaceutical formulations of binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the pharmaceutical formulations of the invention and to methods for producing pharmaceutical formulations.

公开(公告)号：US20210122830A1

公开(公告)日：2021-04-29

申请号：US17003442

申请日：2020-08-26

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Edward N. VAN DEN BRINK ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD, D.M.Sc. ,  David SATIJN ,  Jan VAN DE WINKEL ,  Paul PARREN

IPC: C07K16/30 ,  C07K16/32

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20160067349A1

公开(公告)日：2016-03-10

申请号：US14854613

申请日：2015-09-15

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: A61K47/48 ,  C07K16/30 ,  A61K45/06

CPC classification number: A61K47/48561 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6849 ,  C07K16/30 ,  C07K16/36 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapies and diagnostic methods for using the antibodies and antibody drug conjugates.

Abstract translation: 针对组织因子的抗体药物偶联物。 还公开了包含抗体和抗体药物共轭物的药物组合物，以及使用抗体和抗体药物偶联物的治疗和诊断方法。

公开(公告)号：US20240254252A1

公开(公告)日：2024-08-01

申请号：US17259342

申请日：2019-07-15

Applicant: GENMAB A/S

Inventor： Bart E. C. G. DE GOEIJ ,  Grietje ANDRINGA ,  Frank BEURSKENS ,  Janine SCHUURMAN ,  David SATIJN ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/02

CPC classification number: C07K16/2896 ,  A61P35/02 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

Abstract: Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.

公开(公告)号：US20240228641A9

公开(公告)日：2024-07-11

申请号：US18478711

申请日：2023-09-29

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick ENGELBERTS ,  Kristel KEMPER ,  Esther C. W. BREIJ ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20240132607A1

公开(公告)日：2024-04-25

申请号：US18478711

申请日：2023-09-28

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick ENGELBERTS ,  Kristel KEMPER ,  Esther C. W. BREIJ ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2809 ,  C12N15/63 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/565

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20230321261A1

公开(公告)日：2023-10-12

申请号：US17957302

申请日：2022-09-30

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  A61K45/06

CPC classification number: A61K47/6803 ,  A61K39/001102 ,  A61K45/06 ,  A61K47/6801 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61P35/00 ,  C07K16/2863 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.

公开(公告)号：US20230132049A1

公开(公告)日：2023-04-27

申请号：US17938523

申请日：2022-10-06

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Patrick Engelberts ,  Kristel Kemper ,  Esther C.W. Breij ,  Simone OOSTINDIE ,  Farshid ALEMDEHY

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

Abstract: The invention relates to multispecific antibodies binding to CD3 and CD30. The invention further provides pharmaceutical compositions comprising antibodies of the invention, nucleic acids encoding the antibodies, host cells that produce the antibodies, methods of producing the antibodies and uses of the antibodies, in particular for cancer therapy.

公开(公告)号：US20210317225A1

公开(公告)日：2021-10-14

申请号：US17345628

申请日：2021-06-11

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20210163616A1

公开(公告)日：2021-06-03

申请号：US17172694

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.